Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Combaret

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
European Cytokine Network|August 1, 1990
Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapyM Favrot, R Capdeville, V Combaret, et al.
Cancer Research|June 15, 1992
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinomaJ Y Blay, S Negrier, V Combaret, et al.
Journal of Biological Response Modifiers|April 1, 1990
Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinomaM C Favrot, V Combaret, S Negrier, et al.
British Journal of Cancer|June 1, 1989
Immunological detection of neuroblastoma cells in bone marrow harvested for autologous transplantationV Combaret, M C Favrot, B Kremens, et al.
Oncogene|January 19, 2011
The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor traffickingP Mazot, A Cazes, M C Boutterin, et al.
Oncogene|January 31, 2012
Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cellsC Schönherr, K Ruuth, S Kamaraj, et al.
Early Human Development|September 20, 1996
A 5-year (1990-1994) neuroblastoma screening feasibility study in France. Methodology and preliminary observationsP Mathieu, D Frappaz, F Chauvin, et al.
Medical and Pediatric Oncology|February 1, 1997
Screening for neuroblastoma in France: methodological aspects and preliminary observationsF Chauvin, P Mathieu, D Frappaz, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 1998
Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP)H Rubie, O Delattre, O Hartmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2000
LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosisD Frappaz, J Michon, C Coze, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
European Cytokine Network|August 1, 1990
Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapyM Favrot, R Capdeville, V Combaret, et al.
Cancer Research|June 15, 1992
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinomaJ Y Blay, S Negrier, V Combaret, et al.
Journal of Biological Response Modifiers|April 1, 1990
Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinomaM C Favrot, V Combaret, S Negrier, et al.
British Journal of Cancer|June 1, 1989
Immunological detection of neuroblastoma cells in bone marrow harvested for autologous transplantationV Combaret, M C Favrot, B Kremens, et al.
Oncogene|January 19, 2011
The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor traffickingP Mazot, A Cazes, M C Boutterin, et al.
Oncogene|January 31, 2012
Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cellsC Schönherr, K Ruuth, S Kamaraj, et al.
Early Human Development|September 20, 1996
A 5-year (1990-1994) neuroblastoma screening feasibility study in France. Methodology and preliminary observationsP Mathieu, D Frappaz, F Chauvin, et al.
Medical and Pediatric Oncology|February 1, 1997
Screening for neuroblastoma in France: methodological aspects and preliminary observationsF Chauvin, P Mathieu, D Frappaz, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 1998
Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP)H Rubie, O Delattre, O Hartmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2000
LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosisD Frappaz, J Michon, C Coze, et al.
Pageof 7